STRAINCHEM enters the semi-industrial phase with France Relance.

Last October, the French Government presented the 58 new winners of the Relocation France Relance call for projects. Led by the Ministère de l’Économie, des Finances et de la Relance, this program supports strategic investments in critical sectors, including health, chemistry and agri-food.

One of them is StrainChem, a pharmaceutical company run by Dr.Audrey Serre and Dr.Jean-Jacques Youte, and based on the Biopôle Clermont-Limagne since 2017. It specializes in the synthesis of molecules with high therapeutic potential, biopolymers (e.g., peptide, oligosaccharide, and oligonucleotide) and has developed and patented innovative, efficient, cost-effective and ecological processes to produce these molecules.

The Strainchem project, called SLiPONS (Sustainable LIquid Phase OligoNucleotide Synthesis), aims to set up a production unit for oligonucleotides, molecules used for innovative therapies such as gene therapy. France Relance’s support will accelerate its semi-industrial deployment to meet the needs of pharmaceutical companies, biotechs, and universities. It is expected to create some 20 jobs.

STRAINCHEM
Biopôle Clermont-Limagne
Contact: Jean-Jacques Youte | contact@strainchem.com
Phone: +33 473 670 697